(NASDAQ: IKT) Inhibikase Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.88%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 20.14%.
Inhibikase Therapeutics's earnings in 2025 is -$36,548,986.On average, 1 Wall Street analyst forecast IKT's earnings for 2025 to be -$32,710,278, with the lowest IKT earnings forecast at -$32,710,278, and the highest IKT earnings forecast at -$32,710,278. On average, 1 Wall Street analyst forecast IKT's earnings for 2026 to be -$51,295,663, with the lowest IKT earnings forecast at -$51,295,663, and the highest IKT earnings forecast at -$51,295,663.
In 2027, IKT is forecast to generate -$53,525,909 in earnings, with the lowest earnings forecast at -$53,525,909 and the highest earnings forecast at -$53,525,909.